Overview

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Status:
RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.

Phase:

PHASE4

Details

Lead Sponsor:

Mount Sinai Hospital, Canada

Collaborators:

Kingston Health Sciences Centre
Niagara Health System
Unity Health Toronto

Treatments:

nirmatrelvir and ritonavir drug combination
remdesivir